Partnership to derive clinical insights from global real-world data network
Clinerion (Basel, Switzerland) and Datametrix (Neuchâtel, Switzerland) have jointly announced their partnership aiming to leverage real-world data from Clinerion’s global hospital network to generate clinically relevant real-world evidence.
Clinerion (Basel, Switzerland) and Datametrix (Neuchâtel, Switzerland) have announced their partnership aiming to generate clinically relevant real-world evidence, informing on real-world health outcomes, by leveraging and analyzing real-world data from Clinerion’s global hospital network.
Spearheaded by the US FDA, there have been increasing calls for the generation and integration of high-quality, real-world data into drug development, approval application and manufacturing processes, to limit the number of costly, often infeasible, prospective randomized clinical trials carried out. The value of real-world evidence for post-market safety and surveillance studies has also been noted.
By leveraging Clinerion’s global real-world data network and Datametrix’s analytical capabilities, these partners hope to support pharmaceutical companies by optimizing clinical study designs such that they are reflective of real-world patient experiences, whilst still meeting development needs.
It is hoped that the generation and increased use of real-world evidence could enable pharmaceutical companies to improve patient recruitment for participation in clinical trials, by helping identify both relevant sites and eligible patients at those sites.
Further, by applying complex statistical models to define appropriate endpoints in real-world data studies, Clinerion and Datametrix hope that the accuracy of comparative effectiveness studies that employ real-world data as a comparator arm could be improved.
Ahmed El Rhali, President and CEO of Datametrix, stated: “We believe that data collected in an organized and simple manner, then analyzed using the right analytical tools will empower pharmaceutical and biotechnology companies to bring better drugs to market faster.”
“Together, Datametrix and Clinerion can power real-world evidence research and bring insights in the realities of clinical practice, which is acutely relevant for pharmaceutical industry, field-leading clinicians, hospital management, healthcare policy makers and, of course, patients,” concluded El Rhali.
Source: